In the second quarter of this year, Eli Lilly reported a 48% surge in revenue to $23 billion, while net income reached $7.1 billion.Sales of the company's GLP-1 weight-loss drugs totaled $15 billion, with Mounjaro jumping 91% to $9.9 billion and Zepbound rising 46% to $4.9 billion.@The_Economist_TelegramIn the second quarter of this year, Eli Lilly reported a 48% surge in revenue to $23 billion, while net income reached $7.1 billion.Sales of the company's GLP-1 weight-loss drugs totaled $15 billion, with Mounjaro jumping 91% to $9.9 billion and Zepbound rising 46% to $4.9 billion.@The_Economist_Telegram